Holen Sie sich die Stockscreener-App
106.28
1.96%
-2.13
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$108.41
Offen:
$109.5
24-Stunden-Volumen:
642.29K
Relative Volume:
0.75
Marktkapitalisierung:
$11.66B
Einnahmen:
$1.64B
Nettoeinkommen (Verlust:
$121.85M
KGV:
69.01
EPS:
1.54
Netto-Cashflow:
$-480.40M
1W Leistung:
-1.55%
1M Leistung:
-9.00%
6M Leistung:
-25.91%
1J Leistung:
-19.66%
1-Tages-Spanne:
$106.02
$110.00
1-Wochen-Bereich:
$101.15
$110.00
52-Wochen-Spanne:
$101.15
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie SRPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
106.28 | 11.66B | 1.64B | 121.85M | -480.40M | 1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-11-27 | Bestätigt | Needham | Buy |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
| 2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Sarepta Therapeutics (SRPT) Projected to Announce Quarterly Earnings on Wednesday - MarketBeat
Rhumbline Advisers Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
AlphaCentric Advisors LLC Lowers Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Is Sarepta Therapeutics, Inc. (SRPT) The Best Fast Growth Stock To Buy Right Now? - Insider Monkey
15 Best Fast Growth Stocks To Buy Right Now - Insider Monkey
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Down -8.52% in 4 Weeks, Here's Why Sarepta Therapeutics (SRPT) Looks Ripe for a Turnaround - MSN
Sarepta Therapeutics (NASDAQ:SRPT) Hits New 52-Week LowHere's Why - MarketBeat
Van ECK Associates Corp Raises Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here? - Benzinga
Sarepta Therapeutics Closes $600M in Senior Secured Revolving Credit Facility - citybiz
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Peregrine Capital Management LLC - MarketBeat
Allspring Global Investments Holdings LLC Acquires 84,926 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock - MSN
SRPT Quantitative Stock Analysis - Nasdaq
Solid says early data suggest ‘differentiated’ Duchenne gene therapy - BioPharma Dive
Sarepta stock touches 52-week low at $101.32 amid market challenges - Investing.com
Braun Stacey Associates Inc. Sells 2,990 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Receives Sell Rating from HC Wainwright - MarketBeat
Banque Pictet & Cie SA Has $5.35 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Fiera Capital Corp Sells 9,667 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Arrowhead and Sarepta close $500 million licensing deal - MSN
Sarepta closes on $600M revolving credit facility - MSN
Sovran Advisors LLC Invests $3.21 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics closes on $600M credit facility - TradingPedia
Sapient Capital LLC Cuts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
WCM Investment Management LLC Buys 12,060 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility - Marketscreener.com
Sarepta Therapeutics Closes $600 Million Revolving Credit Facility -February 14, 2025 at 09:08 am EST - Marketscreener.com
Major Banks Back Sarepta With $600M Credit Facility: Financial Power Move Revealed - StockTitan
SRPTSarepta Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Sarepta Q4 Earnings Preview: Rare Disease Leader's Full-Year Performance Revealed - StockTitan
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Gladstone Institutional Advisory LLC - MarketBeat
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results - Business Wire
Deutsche Bank sets Sarepta stock target at $136, cites risks - MSN
Deutsche Bank Initiates Coverage on Sarepta Therapeutics With Hold Rating, $136 Price Target - Marketscreener.com
Tobam Has $3.52 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Arrowhead Secures Massive $825M Deal as FDA Fast-Tracks Breakthrough Drug - StockTitan
Arrowhead Closes Licensing, Collaboration Agreement With Sarepta -February 10, 2025 at 09:39 am EST - Marketscreener.com
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics - BioSpace
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sarepta Therapeutics Inc-Aktie (SRPT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Wigzell Hans Lennart Rudolf | Director |
Dec 12 '24 |
Option Exercise |
13.71 |
10,500 |
143,955 |
33,340 |
| Wigzell Hans Lennart Rudolf | Director |
Dec 12 '24 |
Sale |
124.84 |
10,500 |
1,310,820 |
22,840 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):